Lauren DAngelo
Chief Operating Officer chez ALPHA COGNITION INC.
Profil
Lauren DAngelo is currently the Chief Operating Officer at Alpha Cognition, Inc. She previously worked as the Vice President-Marketing & Commercial Strategy at Urovant Sciences, Inc. Ms. DAngelo completed her undergraduate degree at Florida State University and holds an MBA from the University of Florida.
Postes actifs de Lauren DAngelo
| Sociétés | Poste | Début |
|---|---|---|
| ALPHA COGNITION INC. | Chief Operating Officer | 01/01/2023 |
Anciens postes connus de Lauren DAngelo
| Sociétés | Poste | Fin |
|---|---|---|
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Sales & Marketing | - |
Formation de Lauren DAngelo
| Florida State University | Undergraduate Degree |
| University of Florida | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ALPHA COGNITION INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Health Technology |
